Triplet Platinum-based Combination Sequential Chemotherapy Improves Survival Outcome and Quality of Life of Advanced Non-small Cell Lung Cancer Patients

Chen, Li-Kun; Liang, Ying; Yang, Qun-Ying; Xu, Fei; Zhou, Ning-Ning; Xu, Guang-Chuan; Liu, Guo-Zhen; Wei, Wei-Dong

추천

검색

자료유형: 학술저널

저자정보: Chen, Li-Kun (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Liang, Ying (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Yang, Qun-Ying (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Xu, Fei (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Zhou, Ning-Ning (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Xu, Guang-Chuan (Department of Medical Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Liu, Guo-Zhen (Department of Radiation Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China) Wei, Wei-Dong (Department of Thoracic Oncology, Cancer Center, Sun Yatsen University, State Key Laboratory of Oncology in South China)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제5호

발행연도: 2012.1

수록면: 1,863 - 1,867 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Maintenance chemotherapy is one strategy pursued in recent years with intent to break through the chemotherapy plateau for advanced non-small cell lung cancer (NSCLC). However, given the toxicity, platinum-based combinations are rarely given for this purpose. We carried out the present prospective study of triplet platinum-based combination sequential chemotherapy in advanced NSCLC to investigate if patients could tolerate and benefit from such intensive treatment. Methods: From Dec 2003 to Dec 2007, 190 stage IIIB and IV NSCLC patients in Sun yat-sen University sequentially received the 3 platinum-based combination (TP-NP-GP) treatment (T: paclitaxol175$mg/m^2$ d1; N: vinorelbine25$mg/m^2$ d1 and 8; G: gemcitabine1$g/m^2$ d1 and 8; P: cisplatin20$mg/m^2$ d1-5; repeated every 3 weeks). Patients were followed up to at least 3 years to obtain survival data. Treatment toxicities and the quality of life (QOL) were assessed during the whole treatment. Results: There were 187 patients evaluable. The TP, NP and GP response rates with sequential use were 42.8% (80/187), 41.1% (65/158) and 28.8% (21/73) respectively. Median survival time was 18.2 months and the 1, 2 and 3 year overall survival (OS) rates were 78.7%, 38.5% and 21.3%. Patients receiving > 6 cycles of chemotherapy had significantly longer OS and TTP (MST 25.3 vs. 14.5 months, TTP 15.1 vs. 9.1 months). The QOL on the whole for the patients was improved after chemotherapy. Conclusions: The sequential chemotherapy strategy with triplet platinum-based combination regimens can improve the survival outcome and the quality of life of advanced non-small cell lung cancer patients.

#Sequential chemotherapy #maintenance therapy #NSCLC #platinum-based combinations

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요